Patient preference: weekly injection vs potential monthly depot — 6 month update

NurseKim_ATL said:

There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

Adding the numbers, since they settle part of this. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.

I would rather be corrected than agreed with, if it comes to it.

Dr.SleepRoch said:

I would rather people stopped quoting the 24% as if it were a licensed outcome.

Adding the part of the answer the thread has not reached. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.

Following on from mark_tokyo — and this may be the naive question:

What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?

OP back with an update, since a thread like this is useless without one.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.